SemBioSys announces first quarter 2008 financial and operation...(ements reflect the Company's current exp...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
SemBioSys announces first quarter 2008 financial and operational results
Date:5/9/2008
ements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at http://www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.
SemBioSys Genetics Inc.
Consolidated Balance Sheets
(Unaudited)
-------------------------------------------------------------------------
(expressed in Canadian dollars)
March 31, December 31,
2008 2007
$ $
-------------------------------------------------------------------------
Assets
Current assets
Cash and cash equivalents 16,284,778 20,444,013
Accounts receivable 150,468 583,591
Interest receivable 100,572 30,321
Prepaid expenses and deposits 452,613 538,718
Inv
'/>"/>
| SOURCE SemBioSys Genetics Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. SemBioSys receives milestone payments from AVAC Ltd.
2. SemBioSys initiates toxicology study for safflower-produced insulin
3. SemBioSys announces 2007 financial and operational results
4. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
5. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
6. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
7. SemBioSys signs option agreement for safflower-produced food ingredient
8. SemBioSys announces 2007 third quarter results
9. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
10. SemBioSys updates Apo AI development program
11. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
Post Your Comments:
Breaking Biology Technology:SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance 2SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance 3Eidogen-Sertanty Licenses TIP to the FDA 2Boost for Prostate Cancer Screening - Report Shows Mortality Reduction as High as 31% 2New technology could boost disease detection tests' speed and sensitivity 2
[0] SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance[0] Eidogen-Sertanty Licenses TIP to the FDA[0] Boost for Prostate Cancer Screening - Report Shows Mortality Reduction as High as 31%[0] New technology could boost disease detection tests' speed and sensitivity
Other Biology Technology:Minneapolis company sets sights on southern Wisconsin 2Minneapolis company sets sights on southern Wisconsin 3DEMOfall - A return to simplicity 2DEMOfall - A return to simplicity 3
Breaking Biology News(10 mins):MSU research may lead to new ways to control honeybee parasite 2Gene Therapy Offers Hope for Severe Hereditary Eye Disease 60029 1Gene Therapy Offers Hope for Severe Hereditary Eye Disease 60029 2Surgery potentially best option for severe migraine headaches 60027 1Surgery potentially best option for severe migraine headaches 60027 2Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process 14587 1Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process 14587 2Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process 14587 3
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |